Regeneron Pharmaceuticals: Q2 Earnings Insights

Shares of Regeneron Pharmaceuticals REGN rose 1.5% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share increased 18.54% year over year to $7.16, which beat the estimate of $5.98.

Revenue of $1,952,000,000 up by 0.93% from the same period last year, which beat the estimate of $1,740,000,000.

Guidance

Regeneron Pharmaceuticals hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: Aug 05, 2020

Time: 08:30 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/eobuvqfq

Price Action

52-week high: $664.64

52-week low: $271.37

Price action over last quarter: Up 18.88%

Company Overview

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has six marketed products: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Zaltrap in colorectal cancer; Dupixent in atopic dermatitis, asthma, and nasal polyposis; Libtayo in cutaneous squamous cell carcinoma; Arcalyst in CAPS; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer.

Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNews
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...